Holen Sie sich die Stockscreener-App
10.38
3.08%
-0.33
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress - Investing.com
Lipocine completes enrollment in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug - TipRanks
Lipocine Inc Completes Enrollment in Phase 3 Trial for PPD Treatment - TradingView
Lipocine completes enrollment in phase 3 trial for PPD treatment - Investing.com
At-home postpartum depression drug from Lipocine tested in 90 women - Stock Titan
CEO Moves: Can Lipocine Inc ride the EV waveJuly 2025 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Performance Recap: What is TREEs TAM Total Addressable MarketWeekly Market Outlook & Weekly High Return Opportunities - baoquankhu1.vn
LPCN 1154 for postpartum depression continues clinical process after safety review - Contemporary OB/GYN
Liver Cirrhosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Pfizer, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland - The Globe and Mail
Lipocine’s PPD drug trial continues after positive safety review By Investing.com - Investing.com India
Lipocine’s PPD drug trial continues after positive safety review - Investing.com
Lipocine Advances Phase 3 Postpartum Depression Drug Trial - TipRanks
Lipocine Inc Reports Progress in Phase 3 Trial for PPD - TradingView — Track All Markets
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire
How Lipocine Inc. stock reacts to global recession fearsMarket Activity Report & High Accuracy Investment Entry Signals - ulpravda.ru
How Lipocine Inc. stock performs in stagflationTrade Risk Assessment & AI Forecasted Stock Moves - ulpravda.ru
How Lipocine Inc. stock benefits from strong dollarJuly 2025 Big Picture & Weekly Consistent Profit Watchlists - ulpravda.ru
Why Lipocine Inc. stock is considered a top pickJuly 2025 Big Picture & Fast Gain Stock Tips - Улправда
Why Lipocine Inc. stock could benefit from AI revolutionTrade Performance Summary & Free Fast Gain Swing Trade Alerts - Улправда
What is the fair value of Lipocine Inc. stock nowBear Alert & Reliable Entry Point Trade Alerts - ulpravda.ru
Lipocine price target lowered to $7 from $8 at H.C. Wainwright - MSN
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World
Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154 - MSN
Aug PreEarnings: Can Lipocine Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
Market Pulse: How Lipocine Inc. stock reacts to global recession fearsWeekly Trade Report & Long Hold Capital Preservation Tips - Улправда
Can Lipocine Inc. stock outperform in 2025 bull marketMarket Sentiment Report & Weekly High Return Stock Opportunities - Улправда
Does Lipocine Inc. stock trade at a discount to peersJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - Улправда
Return on equity % of Lipocine Inc. – BOATS:LPCN - TradingView — Track All Markets
Trend Review: Can Lipocine Inc. stock deliver consistent earnings growth2025 Valuation Update & Detailed Earnings Play Alerts - DonanımHaber
How Lipocine Inc. stock performs in high volatility marketsJuly 2025 Snapshot & Fast Gain Stock Trading Tips - DonanımHaber
Financial Review: Lipocine (NASDAQ:LPCN) vs. Astellas Pharma (OTCMKTS:ALPMY) - Defense World
Lipocine reaches 80% enrollment in postpartum depression drug trial By Investing.com - Investing.com Nigeria
Lipocine Advances Phase 3 Trial for PPD Treatment - TipRanks
Lipocine Inc Announces 80% Enrollment in PPD Phase 3 Study - TradingView — Track All Markets
Lipocine reaches 80% enrollment in postpartum depression drug trial - Investing.com India
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire
Lipocine Inc. Announces Resignation of Jeffrey Fink as Director, Effective January 1, 2026 - marketscreener.com
Lipocine Earnings Notes - Trefis
Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting - Investing.com UK
EBIT per share of Lipocine Inc. – BOATS:LPCN - TradingView
Lipocine (LPCN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lipocine Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Lipocine Inc. (LPCN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Why hedge funds are buying Lipocine Inc. stockPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):